4.7 Article

The BATTLE Trial: Personalizing Therapy for Lung Cancer

期刊

CANCER DISCOVERY
卷 1, 期 1, 页码 44-53

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8274.CD-10-0010

关键词

-

类别

资金

  1. Bristol-Myers Squibb
  2. Merck
  3. Novartis
  4. AstraZeneca
  5. Genentech
  6. Amgen
  7. Bayer
  8. Exelixis
  9. GlaskoSmithKline
  10. Pfizer
  11. Department of Defense [W81XWH-6-1-0303]
  12. National Institutes of Health through MD Anderson's Cancer Center [P30 CA016672]

向作者/读者索取更多资源

The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomized study in 255 pretreated lung cancer patients. Following an initial equal randomization period, chemorefractory non-small cell lung cancer (NSCLC) patients were adaptively randomized to erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib, based on relevant molecular biomarkers analyzed in fresh core needle biopsy specimens. Overall results include a 46% 8-week disease control rate (primary end point), confirm prespecified hypotheses, and show an impressive benefit from sorafenib among mutant-KRAS patients. BATTLE establishes the feasibility of a new paradigm for a personalized approach to lung cancer clinical trials. (ClinicalTrials.gov numbers: NCT00409968, NCT00411671, NCT00411632, NCT00410059, and NCT00410189.) SIGNIFICANCE: The BATTLE study is the first completed prospective, adaptively randomized study in heavily pretreated NSCLC patients that mandated tumor profiling with real-time biopsies, taking a substantial step toward realizing personalized lung cancer therapy by integrating real-time molecular laboratory findings in delineating specific patient populations for individualized treatment. Cancer Discovery; 1(1); 44-53. (C) 2011 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据